Pilot Study of Mirtazapine for the Dual Treatment of Depression and Temozolomide-Induced Nausea and Vomiting (CINV) in Newly-Diagnosed High-Grade Glioma Patients on Temozolomide Therapy
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Incidence of Treatment-Emergent Adverse Events
研究概览
简要总结
The purpose of the study is to estimate the ability of mirtazapine to reduce depression, nausea, and vomiting, and maintain weight in depressed glioma patients undergoing Temozolomide (TMZ) therapy. Of equal importance, the investigators will monitor the tolerability of Mirtazapine in these patients over the course of the study.
详细描述
Research Hypothesis: For glioma patients undergoing TMZ chemotherapy, Mirtazapine will address TMZ-associated nausea and vomiting (CINV) and weight loss in addition to depression. Mirtazapine acts as an antagonist at the 5-HT3 receptor, which may explain its anti-emetic properties. Mirtazapine is also an appetite stimulant, which may help curb the weight loss associated with TMZ chemotherapy.
Specific aim 1: To administer the Beck Depression Inventory to approximately 100 patients meeting the inclusion/exclusion criteria in order to identify at least 36 with clinical depression (defined as total score >= 21).
Specific aim 2: To put at least 36 clinically depressed patients identified in aim one on mirtazapine for eight weeks.
Specific aim 3: To administer the Beck Depression Inventory to patients from aim two at four weeks and at eight weeks of treatment with mirtazapine.
Specific aim 4: To document weight and frequencies of nausea, vomiting, and insomnia among participants over the course of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Understand and voluntarily sign and date an informed consent document prior to any study related assessments/procedures are conducted.
- •Histologically confirmed diagnosis of glioma
- •No prior treatment with temozolomide TMZ
- •Patient will receive temozolomide TMZ therapy as part of their standard treatment.
- •Males and Females ≥18 years of age at the time of signing the informed consent document. Able to understand consent forms and study materials in English
- •Willing to use approved methods of contraception for duration of study
- •Karnofsy Performance Score (KPS) of at least 60
- •Patients should have stopped any anti-depressant medications by standard of care at least a month before enrolling in the trial
- •Willing and able to adhere to the study visit schedule and other protocol requirements.
排除标准
- •Prior treatment with other chemotherapy drugs for glioma
- •Known hypersensitivity to Mirtazapine and 5-HT3 receptor antagonists
- •Life expectancy of less than three months
- •Pregnancy or breastfeeding.
研究组 & 干预措施
mirtazapine in glioma patients treated with Temozolomide
Using the well-known Beck Depression Inventory, we will assess the changes in depression scores from baseline to after four and eight weeks of treatment with mirtazapine. We will also assess the change in nausea, vomiting, and weight at the same time points, and collect information on tolerability of mirtazapine throughout the course of the study.
干预措施: Mirtazapine (Remeron) (Drug)
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events
时间窗: 8 weeks
To monitor the adverse event of Mirtazapine over the course of the study. AEs will be graded according to CTCAE V5.
Depression level in glioma patients on temozolomide therapy treated with Mirtazapine
时间窗: 8 weeks
The assessment is conducted using the Beck Depression Inventory. The scoring scale ranges from 1 to 63. Participants with a baseline depression score of 21 or more will be classified as depressed and will be issued a prescription for mirtazapine. Total depression score between baseline and eight weeks will be compared for each patient. Distributional properties of the data will be assessed using appropriate statistical method to examine whether there is statistically significant improvement or not.
Patient Weight Change
时间窗: 8 weeks
To estimate the ability of mirtazapine to maintain weight in depressed glioma patients undergoing Temozolomide (TMZ) therapy. Weight change for each patient between baseline and 8 week will be calculated and analyzed using applicable statistical method.
Frequency and grade of nausea and vomiting in depressed glioma patients on temozolomide therapy treated with Mirtazapine
时间窗: 8 weeks
To assess the patient's level of nausea and vomiting on a nausea/vomiting scale of 1 to 7. Lower value indicates less nausea and vomiting; while higher value indicates more nausea and vomiting. Data will be assessed using appropriate statistical method to examine whether there is statistically significant improvement or not.
次要结局
- Percentage of adherence to mirtazapine regimen(8 weeks)
- Frequency of dose modifications of mirtazapine(8 weeks)
研究者
Daniela A. Bota
Associate Dean, Clinical Research
University of California, Irvine